Functional Brands closes $8 million private placement and completes Nasdaq listing
Scienture Holdings, Inc. (NASDAQ:SCNX) filed a prospectus supplement with the Securities and Exchange Commission on October 24, 2025, increasing the amount of common stock it may sell under its equity distribution agreement with Maxim Group LLC. The aggregate offering price for shares that may be sold has been raised to $9,592,009.
According to the company’s statement in the press release, Scienture Holdings has sold approximately $13,252,250 in gross proceeds of securities under General Instruction I.B.6 of Form S-3 in the prior 12 months. Following the latest filing, $9,592,009 remains available to be sold under the updated prospectus supplement.
The company’s common stock is listed on the Nasdaq Stock Market under the symbol SCNX.
The filing specifies that this report does not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of Scienture Holdings’ common stock in any jurisdiction where such actions would be unlawful before registration or qualification under the relevant securities laws.
This information is based on a statement from the company’s press release filed with the SEC.
In other recent news, Scienture Holdings Inc. has announced significant developments that may interest investors. The company has commenced commercial sales of Arbli™, the first FDA-approved oral suspension formulation of losartan potassium, providing an alternative for patients who cannot take solid dosage forms. This product enters a substantial market, with U.S. losartan sales amounting to approximately $256 million annually. In addition, Scienture Holdings received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, giving the company until April 2026 to regain compliance.
Scienture Holdings has also amended the employment agreements for its top executives, increasing their annual base salaries to $400,000 each. Furthermore, the company has reached an agreement with Arena Finance Markets, LP and Arena Special Opportunities III LP to discharge all outstanding balances on secured convertible debentures. Under this agreement, Arena Investors will convert the remaining amounts owed into shares of Scienture’s common stock. These recent developments highlight the company’s strategic moves in both product innovation and financial management.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.